Categories Earnings, Health Care
Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot
— Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of 2019, compared to a loss of $6.1 million or $0.85 per share last year. Analysts had forecast a loss of $0.61 per share.
— Being a development-stage biopharmaceutical company, Catabasis did nor record revenues in the December-quarter
— Research & Development expenses increased 16% year-over-year to $4.3 million during the three-month period
— At $2.5 million, selling, general and administrative expenses were up 4% from the year-ago period
— As of December 2019, cash, cash equivalents and short-term investments were $36.2 million, compared to $40.6 million as of September 2019
— Expects to fund operations through a potential NDA filing and into the third quarter of 2021, using available cash
— Expects to publish top results from the phase-3 PolarisDMD trial of edasalonexent, in Duchenne muscular dystrophy, in the fourth quarter of 2020
Most Popular
Key highlights from Deere & Company’s (DE) Q1 2025 earnings results
The Deere & Company (NYSE: DE) reported its first quarter 2025 earnings results today. Worldwide net sales and revenues decreased 30% year-over-year to $8.50 billion. Net income was $869 million, or $3.19 per
CSCO Earnings: A snapshot of Cisco’s Q2 2025 report
Cisco Systems Inc. (NASDAQ: CSCO), a leading manufacturer and distributor of data networking products, on Wednesday reported financial results for the second quarter of 2025. The San Jose-headquartered tech firm
What to look for when Walmart (WMT) reports Q4 results next week
Over the years, Walmart Inc. (NYSE: WMT) has consistently dominated the US grocery market, benefitting from lower prices and its wide product range across categories. After delivering an impressive performance